+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Meningioma Drug"

Meningioma - Pipeline Insight, 2024 - Product Thumbnail Image

Meningioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
Meningioma- Epidemiology Forecast to 2032 - Product Thumbnail Image

Meningioma- Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Meningioma - Pipeline Review, H2 2019 - Product Thumbnail Image

Meningioma - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 349 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Meningioma is a type of brain cancer that affects the membranes surrounding the brain and spinal cord. Treatment for meningioma typically involves surgery, radiation therapy, and chemotherapy. Drug therapy is also used to treat meningioma, and the meningioma drug market is composed of a variety of drugs used to treat the disease. These drugs include corticosteroids, anticonvulsants, and anti-angiogenic agents. Corticosteroids are used to reduce inflammation and swelling, while anticonvulsants are used to control seizures. Anti-angiogenic agents are used to inhibit the growth of new blood vessels, which can help reduce tumor growth. The meningioma drug market is highly competitive, with a number of companies offering various treatments. Some of the major players in the market include Novartis, Pfizer, Merck, and Roche. Other companies such as Bristol-Myers Squibb, Eli Lilly, and AstraZeneca also offer treatments for meningioma. Show Less Read more